Xtandi fails a combo study, blocking a path to continued use for Pfizer, Astellas
One of the studies on the prostate cancer drug Xtandi that Pfizer inherited in its $14 billion buyout of Medivation has failed to deliver …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
